Evidence map›Paper›PMID 41615268›Full record

ArticleJournal of virology2026

HEV replication is promoted by blocking the NF-κB signaling pathway through inhibiting FLNa expression.

Yueping Xia, Shuangfeng Chen, Qiangqiang He, Chao Cong, Feiyang Long, Yuan Wang, Huichan Liu, Mengsi Hu, Xiaoxia Hu, Yujie Shen and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yueping Xia *Life Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.ORCID 0000-0002-4354-4708
Shuangfeng Chen *Life Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Qiangqiang He *Life Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Chao Cong *Life Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Feiyang LongLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Yuan WangLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Huichan LiuLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Mengsi HuLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Xiaoxia HuLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Yujie ShenLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Liangheng XuLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Yunlong LiLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Wenhai YuInstitute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, People's Republic of China.
Daqiao WeiLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Chuanmao ZhangLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.
Fen HuangLife Science and Technology & Medical Faculty, Kunming University of Science and Technology, Kunming, People's Republic of China.ORCID 0000-0001-9147-2537

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide. Filamin A (FLNa), a cytoskeletal protein, is involved in cytoskeleton remodeling to construct a barrier to infection and participates in virus entry and release. However, how HEV enters host cells and how it is sensed by pattern recognition receptors are largely unexplored. In this study, the role of FLNa during HEV infection was evaluated in patients with HEV infection, animal models, and cell cultures. Notably, HEV interacted with FLNa at the early stage of infection and remarkably inhibited the expression of FLNa

Indexed as

FilaminsHepatitis EHepatitis E virusNF-kappa BSignal TransductionVirus ReplicationAnimalsApoptosisHumansImmunity, InnateMiceFilaminsFLNA protein, humanNF-kappa BapoptosiscytoskeletonFLNaHEVNF-κB signaling pathway

Identifiers

PMID41615268
PMCPMC13011458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.